LEIDEN, NETHERLANDS--(Marketwire - September 11, 2009) - Biotech company Pharming Group NV (“Pharming”) (NYSE Euronext: PHARM) today provided an update on its outstanding number of shares following transactions with YA Global Master SPV LTD (“YA Global”).
Under the Standby Equity Distribution Agreement with YA Global, Pharming issued a total of 1,852,230 ordinary shares for a cash consideration of EUR 1.0 million. As a result of the above transactions, Pharming’s total number of outstanding ordinary shares is currently 115,788,785 shares.
About Pharming Group NV
Pharming Group NV is developing innovative products for the treatment of genetic disorders, ageing diseases, specialty products for surgical indications, intermediates for various applications and nutritional products. Pharming has two products in late stage development - Rhucin® for Hereditary Angioedema and human Lactoferrin for use in food products and one product in early stage clinical development - Prodarsan® for Cockayne Syndrome. The advanced technologies of the Company include innovative platforms for the production of protein therapeutics, technology and processes for the purification and formulation of these products, as well as technology in the field of DNA repair (via DNage). Additional information is available on the Pharming website, http://www.pharming.com.
This press release contains forward looking statements that involve known and unknown risks, uncertainties and other factors, which may cause the actual results, performance or achievements of the Company to be materially different from the results, performance or achievements expressed or implied by these forward looking statements.
Contact: Ms. Marjolein van Helmond, Pharming Group NV, T: +31 (0)71 52 47 431 or +31 (0)6 109 299 54
Press Release (PDF): http://hugin.info/132866/R/1340819/320530.pdf
This announcement was originally distributed by Hugin. The issuer is solely responsible for the content of this announcement.
Copyright © Hugin AS 2009. All rights reserved.
